Amylyx Pharmaceuticals, Inc. AMLX Return on equity

Return on equity at other companies

MBX Biosciences, Inc.MBX

-25.7%—

Viking TherapeuticsVKTX

-70%-94.5pp

Crinetics PharmaceuticalsCRNX

-39.2%+14.5pp

VAN

Vivani MedicalVANI

-176.4%+175pp

uniQureQURE

-228.2%-11.6pp

MeiraGTx Holdings plcMGTX

-379.5%—

FAQ

What is Amylyx Pharmaceuticals, Inc.'s return on equity?

Amylyx Pharmaceuticals, Inc. (AMLX) reported return on equity of -74.7% in Q2 2026.

How has Amylyx Pharmaceuticals, Inc.'s return on equity changed year-over-year?

Amylyx Pharmaceuticals, Inc.'s return on equity increased by 14.5% year-over-year, from -87.4% to -74.7%.

What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s return on equity?

Over 2 years (2023 to 2025), Amylyx Pharmaceuticals, Inc.'s return on equity has grown at a 119.9% compound annual growth rate (CAGR), from 12.7% to -61.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.